Skip to NavigationSkip to content

Lilly and Boehringer's Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

Published on 30/07/20 at 12:10pm

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in the treatment of adults with heart failure with reduced ejection fraction, with and without diabetes.

The pair revealed that the 10mg dose of the drug met its primary endpoint in a study of 3,630 participants, successfully reducing the risk of cardiovascular death or hospitalisation as a result of heart failure when used in combination with standard of care.

"Heart failure is a common, but very serious chronic cardiovascular disorder, and it causes substantial disability while threatening the lives of millions of people worldwide," remarked Dr Milton Packer, Chair of the Executive Committee for the EMPEROR study programme and Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center. "The results of the EMPEROR-Reduced trial indicate that SGLT2 inhibitors have the potential to become a new standard of care for this disease, which will be a meaningful addition to currently established treatments."

While detailed findings were not released, it was confirmed that full data from the study would be presented at the European Society of Cardiology (ESC) Congress 2020 in late August.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches